Corbus Pharmaceuticals Announces FDA Orphan Drug Designation for Resunab(TM) for the Treatment of Systemic Sclerosis (Scleroderma)

By: via Benzinga
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.